The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials: [L’efficacité de la combinaison des antagonistes des récepteurs 5-HT3 et du dropéridol ou de la dexamé- thasone est similaire pour prévenir les NVPO. Une méta-analyse d’essais randomisés et contrôlés]
Can J Anesth Habib et al.
51: 311
Additional Material
Files in this Data Supplement:
Appendix -
Studies included in the meta-analysis showing Oxford score, dose regimen in both groups, timing of drug administration and number of patients per group. R/B/D = randomization/blinding/drop-outs; O = ondansetron; G = granisetron; T = tropisetron; Dol = dolasetron; D = droperidol; Dex = dexamethasone; ind = induction; preop = preoperatively; *Pediatric study
Figure 3
-
Forrest plot of trials comparing the efficacy of 5-HT3 receptor antagonists (5-HT3) vs the combination of 5-HT3 receptor antagonists with droperidol (5-HT3 + D) for the prevention of early (0 to 6 hr) and overall (0 to 24 hr) nausea. The central square of each horizontal line represents the relative risk (RR) for each study. The lines demonstrate the range of the 95% confidence interval (95% CI). Weight (%) indicates the influence exerted by each study on the pooled RR. N = sample size; n = number with early or overall nausea. Figures in parentheses are reference numbers to the authors quoted.
Figure 4
-
Forrest plot of trials comparing the efficacy of 5-HT3 receptor antagonists (5-HT3) vs the combination of 5-HT3 receptor antagonists with droperidol (5-HT3 + D) for the prevention of early (0 to 6 hr) and overall (0 to 24 hr) vomiting. The central square of each horizontal line represents the relative risk (RR) for each study. The lines demonstrate the range of the 95% confidence interval (95% CI). Weight (%) indicates the influence exerted by each study on the pooled RR. N = sample size; n = number with early or overall vomiting. Figures in parentheses are reference numbers to the authors quoted.
Figure 5
-
Forrest plot of trials comparing the efficacy of 5-HT3 receptor antagonists (5-HT3) vs the combination of 5-HT3 receptor antagonists with dexamethasone (5-HT3 + Dex) for the prevention of early (0 to 6 hr) and overall (0 to 24 hr) nausea. The central square of each horizontal line represents the relative risk (RR) for each study. The lines demonstrate the range of the 95% confidence interval (95% CI). Weight (%) indicates the influence exerted by each study on the pooled RR. N = sample size; n = number with early or overall nausea. Figures in parentheses are reference numbers to the authors quoted.
Figure 6
-
Forrest plot of trials comparing the efficacy of 5-HT3 receptor antagonists (5-HT3) vs the combination of 5-HT3 receptor antagonists with dexamethasone (5-HT3 + Dex) for the prevention of early (0 to 6 hr) vomiting. The central square of each horizontal line represents the relative risk (RR) for each study. The lines demonstrate the range of the 95% confidence interval (95% CI). Weight (%) indicates the influence exerted by each study on the pooled RR. N = sample size; n = number with early or overall vomiting. Figures in parentheses are reference numbers to the authors quoted.
Figure 7
-
Forrest plot of trials comparing the efficacy of 5-HT3 receptor antagonists (5-HT3) vs the combination of 5-HT3 receptor antagonists with dexamethasone (5-HT3 + Dex) for the prevention of overall (0 to 24 hr) vomiting. The central square of each horizontal line represents the relative risk (RR) for each study. The lines demonstrate the range of the 95% confidence interval (95% CI). Weight (%) indicates the influence exerted by each study on the pooled RR. N = sample size; n = number with early or overall vomiting. Figures in parentheses are reference numbers to the authors quoted.
